Advances in the Understanding of Drug Hypersensitivity: 2012 Through 2022

• Published in: The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 11; no. 1; p. 80
• Main Authors: Macy, Eric, Trautmann, Axel, Chiriac, Anca M, Demoly, Pascal, Phillips, Elizabeth J
• Format: Journal Article
• Language: English
• Published: United States 01.01.2023
• Subjects: Anti-Bacterial Agents; Drug Hypersensitivity - diagnosis; Drug Hypersensitivity - etiology; Drug Hypersensitivity - therapy; Humans; Hypersensitivity, Immediate - etiology; Skin Tests - adverse effects; Drug; Allergy; Anaphylaxis; Patch testing; Hypersensitivity; Skin testing
• ISSN: 2213-2201
• DOI: 10.1016/j.jaip.2022.10.025

Over the last decade there have been key advances in understanding mechanisms, risk, and consequences of both true immunological drug hypersensitivity and unverified drug allergy labels that have changed clinical practice. This has been facilitated by the widespread adoption of electronic health records (EHRs). The vast majority of EHR drug allergy labels are unverified and cause significant morbidity from unnecessary avoidance of optimal drug therapy. There has also been significant movement in our understanding of mechanisms of drug hypersensitivity that, in addition to advancing our understanding of the pathogenesis of immediate and delayed reactions, have guided preventive efforts, diagnostic procedures, and clinical management. More widespread adoption, including scale-up of "allergy" delabeling and appropriate management, specifically for antibiotics, opiates, radiocontrast, chemotherapeutics, biologics, and nonsteroidal anti-inflammatory medications, will be necessary to improve patient outcomes over the next decade. This will require further engagement and collaboration between primary care health care providers, allergists, and other specialists.